-
FBXO39 is inferred to act as a substrate adaptor of an SCF/CRL1 E3 ligase from its F-box+LRR architecture, but its FBXO39-specific substrate repertoire remains poorly established and no validated substrate was reported in the curated literature.
"This is strongly supported as a *family-level mechanism* (xuan2024theemergingand pages 1-2, wang2014rolesoffbox pages 1-3), but **FBXO39-specific substrate repertoire remains poorly established** in the retrieved 2023–2024 literature."
-
FBXO39 is a cancer/testis antigen (BCP-20), testis-enriched and aberrantly re-expressed in tumors, and its knockdown in osteosarcoma cells reduces proliferation and increases apoptosis.
"lentiviral shRNA knockdown of FBXO39 reduced proliferation (Celigo-based counts; MTT assays) and increased apoptosis (Annexin V flow cytometry; caspase 3/7 activity)"
-
An emerging (2026) report proposes FBXO39 promotes colorectal cancer progression and LDHA-mediated aerobic glycolysis via p53 degradation, supported by co-IP and ubiquitination assays, but this is outside the curated window and treated as emerging.
"FBXO39 promotes colorectal cancer progression and LDHA-mediated aerobic glycolysis via **p53 degradation**"